Pulmonary Artery Pressure-Guided Tx Cuts Hospitalizations

Share this content:
Pulmonary Artery Pressure-Guided Tx Cuts Hospitalizations
Pulmonary Artery Pressure-Guided Tx Cuts Hospitalizations

THURSDAY, Feb. 18, 2016 (HealthDay News) -- Ambulatory pulmonary artery (PA) pressure-guided management of heart failure patients is more effective in reducing heart failure hospitalizations than management of patient clinical signs/symptoms alone, according to a study published online Feb. 10 in JACC: Heart Failure.

Maria R. Costanzo, M.D., from the Advocate Heart Institute in Naperville, Ill., and colleagues randomized 550 class III heart failure patients (with a heart failure hospitalization in the prior year) to active monitoring (PA pressure-guided heart failure management plus standard of care) or to the blind therapy group (heart failure management by standard clinical assessment). Participants were followed for a minimum of six months.

The researchers found that after follow-up the active monitoring patients had a higher frequency of medication adjustments; significant increases in the doses of diuretics, vasodilators, and neurohormonal antagonists; targeted intensification of diuretics and vasodilators in those with higher PA pressures; and preservation of renal function despite diuretic intensification.

"Incorporation of a PA pressure-guided treatment algorithm to decrease filling pressures led to targeted changes, particularly in diuretics and vasodilators, and was more effective in reducing heart failure hospitalizations than management of patient clinical signs/symptoms alone," the authors write.

Several authors disclosed financial ties to the medical device industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths